What happens if you stop taking a GLP-1?
Participants regained about two-thirds of lost weight in the year after stopping. What that finding actually means, and what changes the outcome.
The short answer
- In the STEP 1 trial extension, 327 participants followed for a year after stopping semaglutide regained about two-thirds of the weight they had lost.
- The STEP 5 trial followed people on continued semaglutide for 104 weeks and found weight loss of around 15% maintained at two years, along with metabolic improvements.
- The trial participants stopped abruptly and left a structured programme at the same time — the worst-case scenario by design.
The finding
When the STEP 1 trial ended, researchers followed a group of participants for a further year after they stopped taking semaglutide and left the structured lifestyle programme. There were 327 of them.
During the 68 weeks of treatment they lost an average of about 17.3% of their body weight. In the year after stopping, they regained about 11.6 percentage points of it — roughly two-thirds of what they’d lost — finishing about 5.6% below where they started. Cardiometabolic improvements measured during treatment — blood pressure, lipids, blood sugar markers — largely drifted back toward baseline as well.
That is the result. No softening: two-thirds back within a year of stopping.
What it actually means
Now the part headlines leave out, and it is the part that matters. This finding is not evidence that the medication failed. It is evidence about what kind of condition is being treated.
Consider what happens when someone stops a blood-pressure medication: within weeks, blood pressure returns to roughly where it was. Nobody concludes the medication didn’t work, or that the patient lacked discipline. Everyone understands it was managing a condition rather than curing it, and that removing the management returns the condition.
This is the same shape. Obesity behaves as a chronic, relapsing condition, and these medications treat it rather than cure it.
The researchers said as much: the findings confirm the chronicity of obesity and suggest ongoing treatment is required to maintain the improvements.
So here is the honest version nobody selling anything wants to say clearly. This is not a 90-day fix. It is a medication-supported condition, and the realistic frame is management over years rather than a programme with an end date.
If that lands hard, sit with it rather than arguing with it. Most people find it easier once the alternative framing goes away — because the alternative is the one that makes regain into a personal failure, and it is wrong.
The 90-Day Companion — The Companion turns everything on this page into a system: the mechanism explained, the Weekly Body Log, and the prescriber questions in order. Get the Companion, $46.99 →
Three things that are also true
Participants stayed below baseline. A year after stopping, the average was still about 5.6% below where they started. A sustained 5% reduction is associated with meaningful metabolic benefit. Some of the work persisted.
While treatment continues, the loss holds. STEP 5 followed people on continued semaglutide for 104 weeks and found weight loss of around 15% maintained at two years. The regain finding is about stopping, not about decay while treating.
Those participants stopped in the worst possible way. They came off the medication and out of the structured programme simultaneously, by trial design. That is not the only way to stop. Stopping deliberately, with a clinician, with habits already built and a plan for what replaces the medication’s effect, is a materially different situation. There is less research on that than anyone would like — but it is clearly not the same experiment.
Why people stop
The reasons are mostly not about willpower. Cost, most often. Insurance coverage that changes, ends, or was never there. A formulary decision made by someone who has never met you. Side effects that don’t settle. A planned pregnancy. Reaching a point where you and your clinician agree it is reasonable to try. Or simply not wanting to be on a medication indefinitely — a legitimate preference requiring no justification.
Every one of those is a real reason. But they differ in one respect that predicts what happens next.
What changes the outcome isn’t why you stop. It’s whether you stop with a plan and a clinician — or whether it just stops, because a prescription lapsed and nobody noticed.
The second is distressingly common, especially with prescribing services that have no follow-up architecture. A card fails, coverage changes, the service goes quiet, and the medication ends on a Tuesday with no conversation. That is the worst version, and it is avoidable — which is why securing real follow-up care before you need it matters so much.
What to do with this
Build the habits now, while it’s cheap. Protein patterns, resistance training, sleep, and the eating structures you build while appetite is suppressed are yours regardless of what happens to your prescription. They are the part that doesn’t depend on a pharmacy. Start with protein and protecting lean mass.
Know your access situation before it’s urgent. What does your coverage actually say? When does it renew? What happens if you change jobs? Does your prescriber handle prior authorizations? Knowing this in a calm month is very different from discovering it in a bad week.
Have the conversation early. “What’s the plan if I need to stop, or if coverage changes?” is an excellent question to ask while everything is going well. It takes ninety seconds, and it means the answer exists before you need it.
Not ready? Start with The First Week Survival Pages — free — one PDF, sent to your email, no card.
Common questions
How much weight do people regain after stopping a GLP-1?
In the STEP 1 trial extension, 327 participants followed for a year after stopping semaglutide regained about two-thirds of the weight they had lost. Mean loss was about 17.3% during treatment; they regained about 11.6 percentage points, finishing roughly 5.6% below baseline. Cardiometabolic improvements largely drifted back toward baseline too.
Does that mean the medication didn't work?
No. It means the treatment was managing a condition rather than curing it. When someone stops a blood-pressure medication, blood pressure returns to where it was, and nobody concludes the drug failed. Obesity behaves as a chronic, relapsing condition, and these medications treat it rather than cure it.
Does weight loss hold if you stay on the medication?
The STEP 5 trial followed people on continued semaglutide for 104 weeks and found weight loss of around 15% maintained at two years, along with metabolic improvements. The regain finding is specifically about stopping, not about decay during treatment.
What makes stopping go better?
The trial participants stopped abruptly and left a structured programme at the same time — the worst-case scenario by design. Stopping deliberately, with a clinician, with habits already established, is a materially different situation. What most changes the outcome is whether you stop with a plan, or whether it just stops because a prescription lapsed.
Where this comes from
FDA prescribing information for the approved GLP-1 receptor agonists; the peer-reviewed trial literature (STEP, SURMOUNT, SELECT); and Nutritional priorities to support GLP-1 therapy for obesity, the 2025 joint advisory of the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. We use no influencer, telehealth-marketing, or supplement-industry sources.
Educational content from The Reset Series. Not medical advice, not a diagnosis, and no dosing guidance — dose decisions belong to the clinician who wrote your prescription. If you have symptoms that concern you, contact your prescriber. In an emergency, call 911. We are not affiliated with any pharmaceutical company; we sell no medications and provide no prescriptions.